Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 40,000 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 40,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the transaction, the senior vice president owned 1,274 shares of the company’s stock, valued at approximately $127,400. This represents a 96.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Jolanda Howe also recently made the following trade(s):

• On Monday, August 3rd, Jolanda Howe sold 1,840 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $105.29, for a total value of $193,733.60.
• On Wednesday, July 1st, Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $120.00, for a total value of $326,520.00.
• On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $101.95, for a total value of $264,458.30.

Mirum Pharmaceuticals Price Performance

Shares of MIRM stock opened at $102.24 on Thursday. The stock’s fifty day simple moving average is $111.31 and its 200 day simple moving average is $102.02. Mirum Pharmaceuticals, Inc. has a one year low of $63.23 and a one year high of $130.00. The firm has a market cap of $6.64 billion, a price-to-earnings ratio of -7.03 and a beta of 0.52. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The company had revenue of $176.24 million for the quarter, compared to the consensus estimate of $166.33 million. During the same period in the previous year, the business posted ($0.12) earnings per share. The firm’s revenue was up 37.9% compared to the same quarter last year. On average, analysts expect that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on MIRM shares. Weiss Ratings upgraded shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday, August 6th. TD Cowen reduced their price objective on Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Wall Street Zen lowered Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Thursday, August 6th. Finally, Stifel Nicolaus set a $136.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $137.33.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several large investors have recently made changes to their positions in MIRM. Cullen Frost Bankers Inc. bought a new stake in shares of Mirum Pharmaceuticals during the 4th quarter worth about $30,000. Eurizon Capital SGR S.p.A. acquired a new stake in Mirum Pharmaceuticals during the fourth quarter worth approximately $32,000. CIBC Private Wealth Group LLC bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth $32,000. Quantbot Technologies LP bought a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter worth approximately $33,000. Finally, Comerica Bank raised its stake in Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares in the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.